WebCounties are instructed to submit their data for July, August and September 2016 on the new CF 296 reporting form due October 20, 2016. If the consortium does not have the form completely programmed into the system, the counties are to provide whatever data they have available for these months. WebJan 24, 2024 · Last Action: 01/24/22: WITHDRAWN : Bill Request Number: Last updated: 2/8/2024 2:57 PM (EST). About. Contact Us; Career Opportunities
Efficacy assessment of lysin CF-296 in addition to daptomycin or ...
WebJul 19, 2024 · YONKERS, N.Y., July 19, 2024 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents... WebApr 11, 2024 · The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to … gg allin res erected
Press Releases :: ContraFect Corporation (CFRX)
Web1 hour ago · Shewmake was the bright spot in an otherwise atrocious performance from the Stripers. The Atlanta Braves had a day off on Thursday, and that made their minor league system the center of attention for the day. Unfortunately that turned into a frustrating evening as the system got swept thanks to some unexciting offensive performances. WebAug 15, 2024 · Furthermore, either exebacase or CF-296, used in addition to systemically administered daptomycin, also resulted in significant reduction in MRSA counts on infected implants compared to daptomycin ... WebThe manuscript published in Antimicrobial Agents and Chemotherapy, a leading peer-reviewed journal dedicated to the study of infectious diseases, presented data from a study of CF-296 in a preclinical rodent model of acute … christ the redeemer roman catholic church va